相关实验视频

Updated: May 21, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

瘤治疗领域通过诱导NSCLC模型中的免疫细胞死亡来改善CCL2/8和CXCL9/CXCL10表达来增强抗PD疗法

Wei Lin^1,2,3,4, Yingying Wang⁵, Minghao Li⁶

¹Department of Rheumatology and Autoimmunology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, 250014, China. linw1978@163.com.

|March 18, 2025

概括

瘤治疗场 (TTFields) 与抗PD免疫疗法相结合,通过改善瘤免疫微环境,增强非小细胞肺癌 (NSCLC) 治疗. 这种组合疗法增加了T细胞的透,并增强了抗PD疗法的疗效.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
癌症研究癌症研究

背景情况:

非小细胞肺癌 (NSCLC) 是一种普遍存在的恶性瘤.
结合抗PD免疫治疗的瘤治疗场 (TTFields) 是一个有前途的治疗策略.
在NSCLC中这种联合治疗的确切作用机制仍未得到充分研究.

研究的目的:

为了阐明TTFields与抗PD免疫治疗相结合的作用机制 (MOA).
研究这种组合疗法如何改善瘤免疫微环境 (TIME).

主要方法:

利用NSCLC的小鼠模型来评估TTFields用抗PD-1和抗PD-L1免疫疗法的治疗.
采用RNA测序 (RNA-seq) 来识别组合和抗PD治疗组之间的差异基因和途径.
进行了体外实验,以验证TTFields对瘤细胞,T细胞透和免疫死亡标志物的影响.

主要成果:

与对照组相比,组合治疗显著降低了瘤的重量和体积.
RNA-seq确定了1,745个差异表达的基因,包括高调节的免疫和免疫原性细胞死亡 (ICD) 途径.
TTFields疗法增加了T细胞透和关键免疫相关基因 (ATP,HMGB1,CCL2,CCL8,CXCL9,CXCL10) 和炎症类细胞因子的表达,从而改变了TIME并提高了抗PD疗法的疗效.

结论:

TTFields通过促进CD4+和CD8+T细胞透来提高抗PD免疫疗法的有效性.
这种增强是通过诱导ICD来实现的,它增加了瘤细胞中特定化学因子 (CCL2 / 8,CXCL9 / 10) 的表达.
这些发现为TTFields与NSCLC的抗PD疗法相结合的临床应用提供了理论基础和新的见解.

关键词:

化学因子 (chemokines) 是一种化学物质.免疫原性细胞死亡非小细胞肺癌是非小细胞肺癌.透T细胞的透情况瘤治疗领域的瘤治疗领域.抗PD免疫治疗的免疫疗法

更多相关视频

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...